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Abstract
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with isolated 
thrombocytopenia and hemorrhagic risk. While many children with ITP can be safely observed, 
treatments are often needed for various reasons, including to decrease bleeding or improve health 
related quality of life (HRQoL). There are a number of available second-line treatments, including 
rituximab, thrombopoietin-receptor agonists, oral immunosuppressive agents, and splenectomy, 
but data comparing treatment outcomes are lacking. ICON1 is a prospective, multi-center, 
observational study of 120 children starting second-line treatments for ITP designed to compare 
treatment outcomes including platelet count, bleeding, and HRQoL utilizing the Kids ITP Tool 
(KIT). While all treatments resulted in increased platelet counts, romiplostim had the most 
pronounced effect at 6 months (p=0.04). Only patients on romiplostim and rituximab had a 
significant reduction in both skin-related (84% to 48%, p=0.01 and 81% to 43%, p=0.004) and 
non-skin-related bleeding symptoms (58% to 14%, p=0.0001 and 54% to 17%, p=0.0006) after 1 
month of treatment. HRQoL significantly improved on all treatments. However, only patients 
treated with eltrombopag had a median improvement in KIT scores at 1 month that met the 
minimal important difference (MID). Bleeding, platelet count, and HRQoL improved in each 
treatment group, but the extent and timing of the effect varied among treatments. These results are 
hypothesis generating and help to improve our understanding of the effect of each treatment on 
specific patient outcomes. Combined with future randomized trials, these findings will help 
clinicians select the optimal second-line treatment for an individual child with ITP.
Clinicaltrials.gov NCT01971684
Keywords
Immune thrombocytopenia; Rituximab; Thrombopoietin Receptor Agonists; quality of life
Introduction
Immune thrombocytopenia (ITP) is an immune-mediated disorder characterized by isolated 
thrombocytopenia without an identifiable cause.1 The majority of children with ITP present 
with platelet counts below 20 ×109/L which lead to variable bleeding manifestations, as well 
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as symptoms and activity restrictions that impact health-related quality of life (HRQoL). 
Current guidelines for the management of newly diagnosed patients with ITP suggest 
observation in the absence of bleeding symptoms, or treatment with standard first-line 
therapies (corticosteroids, anti-RhD immunoglobulin, or intravenous immunoglobulin 
(IVIG)) for those with bleeding symptoms.2 In the Pediatric and Adult Registry on Chronic 
ITP, 38-47% of the children who received upfront treatment required second-line therapies 
at 6-24 months.3 Reasons for treating patients with second-line therapies may include 
refractory disease, bleeding symptoms or risk of bleeding, poor perceived quality of life, 
need for peri-procedural management, and/or desire to achieve remission.
An International Working Group proposed criteria for assessing outcomes in ITP trials, 
including specific platelet responses, as well as additional outcomes of bleeding symptoms 
and HRQoL assessments.1 Nonetheless, there are limited studies reporting platelet counts, 
bleeding, and HRQoL outcomes for second-line therapies, and none directly comparing 
treatments.4 With an increasing number of available therapies, including the emergence of 
thrombopoietin-receptor agonists for pediatric use,5 the selection of the optimal second-line 
agent remains challenging. Each treatment has differences in cost, mode of administration, 
time to response, rate of response, monitoring requirements, tolerability, and toxicity, adding 
to the difficulty in comparison. This highlights major gaps in available evidence to guide 
clinical decision-making when initiating second-line therapy for pediatric ITP.
ICON1 is a prospective, longitudinal cohort study conducted by the Pediatric ITP 
Consortium of North America (ICON) that followed pediatric patients starting second-line 
treatments for ITP. In this report, we describe the results of a comparison of second-line 
treatments with respect to platelet count, bleeding symptoms, and HRQoL.
Methods
Patients and Treatments:
ICON1 is a longitudinal observational cohort of 120 children with ITP requiring second-line 
treatments.6 Participants were enrolled at 21 centers in the United States and Canada 
between September 2013 and December 2015 following local institutional review board/
research ethics board approval. Consent was provided by caregivers and assent by the 
participants if age appropriate for participation in the study. Enrollment requirements 
included: age 1-17 years and starting a second-line treatment as monotherapy. Second-line 
treatments included all treatments except observation, IVIG, corticosteroids, or anti-D 
immunoglobulin. Patients with secondary ITP were included unless they had Evans 
syndrome with prior or ongoing autoimmune hemolytic anemia. After consent was obtained, 
treatment was initiated according to the preferences of the physician and patient.
Data forms were completed at baseline and 1, 6, and 12 months after starting treatment. 
Baseline and follow-up demographic and clinical characteristics were recorded, including 
disease duration, bleeding scores, rescue therapy, and platelet counts. Duration of ITP was 
defined as chronic in those with ITP for ≥12 months, persistent in those with ITP for 3-<12 
months, and newly diagnosed in those with ITP for <3 months from initial diagnosis.
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Treatments were selected for comparison in this analysis if there were at least 15 evaluable 
patients in the study cohort. Physicians were asked at each timepoint for their assessment of 
the patient’s adherence to the treatment.
Platelet Response:
Platelet counts were collected as per clinical indications. A complete platelet response (CR) 
was defined as ≥50% of platelet counts >100 × 109/L since the prior study visit. A partial 
platelet response (PR) was defined as ≥50% of platelet counts >30 × 109/L and twice the 
baseline platelet count. No response (NR) was defined as any platelet count change that did 
not meet criteria for CR or PR. Using these definitions, the platelet response was compared 
by the change in response category from the baseline visit. The platelet response was 
evaluated for individual treatments, as well as compared between treatment groups. The 
frequency of patients with a single platelet count response of >100 × 109/L or >30 × 109/L 
and a doubling from the baseline platelet count was also reported separately for each 
treatment over the duration of the study. Platelet counts measured ≤30 days after the date of 
rescue medication were excluded from calculations of platelet response.
Bleeding Response:
Bleeding was characterized by score on the ITP Bleeding scale (IBLS), a validated measure 
for use to assess bleeding in childhood ITP in clinical trials.7 The IBLS was used to assess 
worst bleeding in the week prior to the baseline visit and between the 1, 6 and 12 month 
visits after starting treatment. The change in bleeding score from baseline to 1 month and 
between baseline and 6 months were used for the primary analysis while the change in 
bleeding score between baseline and 12 months was assessed as a secondary analysis. The 
IBLS scores bleeding at 9 different sites and grades most sites as 0 (no bleeding), 1 (mild to 
moderate bleeding), or 2 (significant bleeding). For the analysis, the scores were 
dichotomized into grade 0 versus grade 1 or 2 bleeding and into skin versus non-skin 
bleeding. The change in bleeding was evaluated on the individual treatments and also 
compared between treatment groups.
Rescue Treatment:
Response was also characterized by whether treatment with a rescue medication, such as 
corticosteroids or IVIG, was needed between visits. For the primary analysis, the need for 
rescue was assessed between 0 and 1 month and between 0 and 6 months. The use of rescue 
medications was dichotomously analyzed for each treatment and then compared between 
treatment groups.
Health-Related Quality of Life:
HRQoL was measured at baseline, 1 month, and 12 months after starting treatment using the 
Kids ITP Tool (KIT), which is scored from 0-100 with higher scores consistent with better 
quality of life. The KIT is a valid and reliable measure of HRQoL for use in clinical trials of 
childhood ITP.8 The child KIT was completed in children ≥7 years and older, and the parent 
proxy KIT in parents of children ≥2 years of age. For the primary analysis, the change in 
child KIT score was calculated from baseline to 1 month for each participant. As a 
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secondary analysis, the change in child KIT score from baseline to 12 months was also 
evaluated. For those with missing child KIT scores due to age, the parent proxy KIT scores 
were used (n=24). The correlation between the child KIT score and parent proxy score for 
patients who had both was r=0.58 (n=71). The minimal important difference (MID) of the 
KIT has been determined to be a difference of 9 points.9 The change in KIT score on the 
individual treatments was evaluated for both statistical significance and to assess if the 
change surpassed the MID. The change in KIT score was also compared between treatment 
groups.
Statistical Methods:
The data were collected using REDCap and analyzed with SAS v9.4 (Cary, NC). Primary 
outcomes were: bleeding (as defined by skin and non-skin bleeding events); the need for 
rescue medication; platelet response (a 3-level variable: complete, partial, and no response); 
and change from baseline child KIT scores. Due to patient attrition at the 12 month follow-
up, only data from the baseline, 1 month, and 6 month time points were considered in the 
primary analysis when testing for the effect of the treatment group. The data are analyzed 
based on the patients remaining on individual treatments at each timepoint. The visit time 
point was treated as a categorical variable. To take into account the repeated measures nature 
of the data, Generalized Estimating Equations models were used (SAS Proc Genmod). 
These models tested for an interaction between treatment group and visit and, when the 
interaction was not significant, looked for main effects of treatment group. For skin and non-
skin bleeding, the models were logistic, with the bleeding outcome collapsed to two 
categories. The platelet response outcome was multinomial (complete response, partial, and 
no response). Time to first rescue medication was analyzed with a survival analysis. In a 
single analysis, when pairwise comparisons were made between the four treatment groups, 
the Tukey method was used to adjust for chance findings due to multiple comparisons, and 
adjusted p values<0.05 were considered significant. No adjustment was made for the number 
of analyses and thus findings should be interpreted as hypothesis-generating.
Results
ICON1 Demographics
One hundred twenty patients were enrolled on ICON1 and started on the following second-
line treatments: rituximab (43/120, 36%), romiplostim (31/120, 26%), eltrombopag (20/120, 
17%), oral immunosuppressant agents (19/120, 16%), splenectomy (4/120, 3%), and 
dapsone (3/120, 3%). Oral immunosuppressant agents included 6-mercaptopurine (n=13), 
azathioprine (n=1), mycophenolate (n=3), and sirolimus (n=2). Children had received a 
median of 3 prior treatments (range 0-8), with 47 (39%) patients having received at least one 
prior second-line treatment, including rituximab (n=12, 10%), romiplostim (n=11, 9%), 
eltrombopag (n=10, 8%), 6-mercaptopurine/azathioprine (n=6, 5%), and/or splenectomy 
(n=3, 3%). Two patients had not received prior treatments and had been managed with 
observation alone.
Table 1 shows the demographic and clinical features of the cohort overall, in which 19 
(17%) were newly diagnosed, 34 (30%) persistent, and 60 (53%) chronic. Treatment groups 
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were not different with regard to the number of patients with chronic ITP (p=0.97) or 
previous treatment with second-line agents (p=0.10, Table 1). There were no differences 
between the treatment groups at baseline with respect to age, platelet count, bleeding score, 
or physician’s perception of patient adherence to previous medications and/or clinical care.
Patient attrition was seen at all time points post-baseline (Table 1). Patients dropped out of 
their treatment group for various reasons, including: treatment failure by platelet count or 
bleeding (n=19), patient lost to follow up (n=8), clinical or laboratory side effects from 
treatment (n=4), patient preference (n=4), switched to dual therapies (n=3), developed 
autoimmune hemolytic anemia (n=3), investigator withdrew patient (n=2),and effect waned 
(n=1). Overall, the rate at which patients left their treatment group was similar among 
treatments except for oral immunosuppressants, which had the highest rate of attrition (Table 
1). Among the patients taking oral immunosuppressants, primary reasons for leaving the 
treatment were continued bleeding or thrombocytopenia (n=8) and side effects or lab 
toxicity (n=3).
Treatment Outcomes
Platelet Response—The numbers of platelet assessments between clinical visits varied 
widely, with a mean number of total platelet assessments of 6 (range 1-15). Romiplostim 
treated patients had a significantly greater number of platelet counts checked between visits 
compared with all other treatments (8 vs. 5, p<0.001). The median platelet count 
significantly increased from baseline in all treatment groups: rituximab, eltrombopag, 
romiplostim, and oral immunosuppressants (Table 2, Figure 1A). At the one month visit, 
platelet count response rates did not significantly vary between treatments (p=0.71, Table 2, 
Supplemental Table). CR rates 1 month after starting treatment ranged from 13% in the 
group receiving oral immunosuppressants, 19% in the rituximab group, 21% in the 
romiplostim group, to 30% in the eltrombopag group. Combined CR/PR rates 1 month after 
starting treatment ranged from 32% in the oral immunosuppressant group, 52% in the 
romiplostim group, to 55% in both the rituximab and eltrombopag groups (p=0.41).
Response to treatment varied significantly among treatments at 6 months (p=0.04), at which 
time, patients treated with romiplostim had the highest CR/PR (83%) compared to the other 
treatments with CR/PR of oral immunosuppressants 38%, eltrombopag 67%, and rituximab 
79%. Patients treated with rituximab and romiplostim also had a statistically significant 
increase in CR/PR from 1 to 6 months (p=.0003, p=.0001, respectively). Therefore, many 
patients who had not had a CR/PR by 1 month on rituximab and romiplostim went on to 
respond between 1 and 6 months after starting treatment whereas CR/PR rate was stable 
between 1 and 6 months in those receiving eltrombopag and oral immunosuppressants.
A single platelet count response >100 × 109/L occurred by 1 month for 45% on rituximab 
(77% at 6 months), 65% on eltrombopag (67% at 6 months), 48% on romiplostim (88% at 6 
months), and 27% on oral immunosuppressants (38% at 6 months). A single platelet count 
response >30 × 109/L and a doubling from the baseline platelet count occurred by 1 month 
for 60% on rituximab (90% at 6 months), 75% on eltrombopag (80% at 6 months), 62% on 
romiplostim (92% at 6 months), and 40% on oral immunosuppressants (40% at 6 months). 
Differences in response were statistically significant at 6 months using either criteria of 
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platelet response (>100 × 109/L or >30 × 109/L, p=0.04 and p=0.007, respectively); in each 
case, platelet response to oral immunosuppressants was only about half that of other 
treatments.
Bleeding Outcome—Grade 2 skin-related bleeding occurred in 47 (42%) patients at 
baseline and 12 (11%) patients at 1 month, 5 (6%) at 6 months, and 3 (5%) at 12 months. 
Grades 1 and 2 skin-related bleeding symptoms improved over time in all treatments 
(p<0.001, Table 3, Figure 1b). Comparing treatments, there was no significant difference in 
skin-related bleeding at any of the time points (p=0.98 at baseline, p=0.41 at 1 month, 
p=0.29 at 6 months, and p=0.27 at 12 months). In patients treated with romiplostim, 
rituximab, and oral immunosuppressants, grades 1 and 2 skin-related bleeding significantly 
improved from baseline to the 1 month visit (p=0.01, p=0.0004,and p=0.04, respectively). 
However, from baseline to 6 months, skin-related bleeding symptoms were significantly 
improved only in those patients receiving romiplostim and rituximab (p=0.02 and p=<0.001, 
respectively).
Grade 2 non-skin bleeding occurred in 29 (26%) of patients at baseline and 11 (10%) at 1 
month, 6 (8%) at 6 months, and 2 (3%) at 12 months. Grades 1 and 2 non-skin bleeding 
symptoms improved over time in all treatments (p<0.001, Table 3, Figure 1b). Comparing 
between treatments, there was no significant difference in the degree of non-skin bleeding 
(p=0.95 at baseline, p=0.54 at 1 month, p=0.17 at 6 months, and p=0.28 at 12 months). In 
patients taking romiplostim and rituximab only, grades 1 and 2 non-skin bleeding 
significantly improved from baseline to the 1 month visit (p=0.0001 and p=0.0006, 
respectively). Only patients on rituximab had a significant improvement in non-skin 
bleeding from baseline to 6 months (p=0.003, Table 3).
Rescue Therapy—The use of rescue therapy was similar among treatments between 
baseline and 1 month (16-25%, p=0.88) and between baseline and 6 months (21-44%, 
p=0.22). There was no difference among treatments with regard to the time until a rescue 
therapy was used. However, between 1 and 6 months, the patients treated with rituximab and 
romiplostim used significantly less rescue therapy, 6.1% and 12.5% respectively, as 
compared with those treated with oral immunosuppressants or eltrombopag, 37.5% and 
40%, respectively (p=0.0099).
Health-Related Quality of Life—The baseline report of HRQoL was different between 
the treatment groups with children receiving rituximab reporting significantly lower pre-
treatment KIT scores (p=0.02). At 1 month, the mean KIT scores, adjusted for baseline, 
were not different among treatments (p=0.32). This was also true at 12 months (p=0.43).
From baseline to 1 month, KIT scores significantly improved for rituximab (p=0.0001), 
romiplostim (p=0.0003), eltrombopag (p=0.0008), and oral immunosuppressants (p=0.0006, 
Table 4). At the 12 month time point, the KIT score was also significantly improved over the 
baseline time-point for all treatment groups (Table 4).
The median improvement from baseline to 1 month met the threshold for the MID for 
eltrombopag (median change = + 10.9), whereas the median changes in score for the other 
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treatment groups were below this threshold. However, the percent of patients who had an 
individual change in KIT scores that met the threshold for the MID was not different 
between the treatment groups at 1 month (37-55% of each treatment group, p=0.61). At the 
12 month time-point, the rituximab and eltrombopag treatment groups had significantly 
more patients whose change in KIT scores met the MID (80% and 70% respectively) as 
compared with the oral immunosuppressant and romiplostim groups (25% and 21% 
respectively, p=0.001).
Discussion
Children with ITP are treated with second-line therapy for a variety of reasons including 
bleeding, risk of bleeding, fatigue, activity restrictions, and poor quality of life, among 
others. Given this diversity of reasons for which second-line treatment is initiated, providers 
need to understand the effect of each treatment on these outcomes to select the best 
treatment for an individual patient. Currently, selecting a specific treatment is challenging 
because there are no randomized controlled trials directly comparing the available treatments 
and no existing algorithms to follow. Furthermore, in single arm studies, outcomes beyond 
platelet count are often not well-described. This prospective, longitudinal observational 
study is the first to evaluate and compare the efficacy of various second-line therapies for 
ITP in children with a focus on important patient related outcomes including bleeding, 
platelet count, and HRQoL.
Prior studies of ITP treatments have focused on the platelet count as the primary measure of 
efficacy. In this study, the platelet count generally increased from baseline with all 
treatments. The primary analysis used a durable platelet count measure which is clinically 
relevant but more stringent than a number of other reports of second-line treatment which 
used single platelet count measures. While the effect of treatment on the platelet count was 
significant according to all measures, the findings were more pronounced when non-durable 
platelet reponse criteria were used. By 6 months after starting treatment, romiplostim and 
rituximab had the most robust platelet response rate, both in terms of median platelet count 
and durable platelet response. In this observational study, the role of observed adherence 
may have contributed to the efficacy of romiplostim and rituximab, given that both are 
administered in the hospital setting, and dietary interactions with eltrombopag were not 
rigorously monitored. Many patients who had not responded by 1 month, responded to 
romiplostim and rituximab by 6 months, whereas patients who responded to eltrombopag 
and oral immunosuppressants generally did so by 1 month after treatment initiation. For all 
treatments, the platelet response rates did not significantly change between 6 and 12 months. 
These findings may help guide physicians about when patience and continued treatment are 
appropriate and when a change in therapy should be considered.
Overall rates of grade 2 non-skin bleeding once treatment was started were low. Both skin 
and non-skin related bleeding symptoms improved over time on all treatments with the most 
significant reduction in bleeding in patients on rituximab and romiplostim. Furthermore, 
patients treated with rituximab and romiplostim received significantly less rescue therapy as 
compared with the other treatments.
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HRQoL improved in patients on all treatments, but the greatest effect was seen in both the 
eltrombopag and rituximab groups, although these groups had the lowest baseline KIT 
scores. Clinicians may be more likely to select rituximab as a second-line agent in patients 
with a greater impact from ITP on everyday life due to the upfront nature of dosing and the 
longer effect of the treatment, if successful, on the patient’s platelet count.10,11 Rituximab is 
typically administered intravenously for a total of four weekly doses with no medication 
administration between the 1 and 6 month timepoints. Given this schedule of administration 
and the effect on platelet count and bleeding, the HRQoL improvement is not surprising. 
The positive effect of eltrombopag on HRQoL may be due to the combination of the oral 
administration and its improvement in platelet count and bleeding.
This analysis did not systematically address additional outcomes of interest, such as 
potential side effects and cost. An earlier cost per response analysis slightly favors 
romiplostim over eltrombopag in adults with ITP.12 Eltrombopag and romiplostim appear to 
be equivalent in terms of safety in a systematic review including nine randomized trials in 
786 adults, using an indirect comparison design.13 The side effect profile and cost of 
rituximab and oral immunosuppressants have not been directly compared to the 
thrombopoietin-receptor agonists in a meaningful way. The mechanisms of action and the 
routes of administration are also considerations in the selection of these agents. Specific 
treatments are often selected by parent and/or patient preference which may be why patients 
showed an increase in HRQoL across treatments.6 If patients and families engage in the 
selection of their treatment, it will increase the likelihood that the therapy will match their 
lifestyles and goals, ultimately increasing HRQoL.
Though splenectomy can offer a durable response rate of approximately 70%, the response 
cannot be predicted in a given patient, and there are associated risks.14,15 Providers enrolling 
in the ICON1 study reported that they chose splenectomy for its curative potential; however, 
very few were performed during the several years of this study.16 Splenectomy rates have 
been consistently declining over time with the increased use of pharmacologic therapies.17 
Only 4 patients in this cohort underwent splenectomy during this study, consistent with this 
trend. Immunosuppressive agents were among the earliest therapies for steroid refractory 
ITP, but given the relatively low efficacy and potential for significant toxicity, their use is 
limited.18 These data support that physicians are choosing these therapies less frequently, 
and these agents clearly resulted in less improvement in platelet count, bleeding, and 
HRQoL than the other treatments.
Due to the real world nature of the study cohort, there was patient attrition at each study time 
point after baseline for a variety of reasons including lack of efficacy, side effects, remission, 
and lack of follow up. With this attrition, the cohort at 6 and 12 months is likely over-
representative of responders. To partially account for this limitation, the 12 month time-point 
was used as a secondary analysis while the 1 and 6 month time points were used in the 
primary analysis. An additional limitation of this observational study is that medications 
may not have been dosed or titrated similarly among centers or patients, even though dosing 
regimens are standardized for these treatments. Additionally, platelet count surveillance was 
variable among centers and providers. Platelet counts were collected as per clinical 
indications; thus, the numbers of platelet assessments between clinical visits varied between 
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centers. We combined grade 1 and 2 bleeding in the assessment of change in bleeding over 
time due to the low rate of grade 2 bleeding. This combination of bleeding grades may not 
give an accurate assessment of change in the most severe bleeding. Lastly, because 
physician-patient teams determined optimal treatment independently, several treatment 
options did not have enough patients to meaningfully analyze outcomes. For this reason, the 
group of oral immunosuppressants represents a more heterogenous treatment group, which 
may have impacted the overall outcomes. Many of these factors also contribute to the 
difficulties of designing randomized trials to compare these treatments. In the absence of any 
randomized trials, this study provides hypothesis-generating findings for future studies and 
randomized trials. Despite these limitations, this study’s approach has allowed for an 
assessment of second-line treatments in pediatric ITP with regard to the efficacy of 
individual treatments and comparisons between treatments.
Overall, bleeding, platelet count, and HRQoL all improved in each treatment group. 
Nevertheless, there were important differences among the treatments, with certain treatments 
having a greater effect on bleeding and the platelet count and others having a greater effect 
on HRQoL. Given these findings, it is clear that clinicians should weigh and balance the 
reasons for treatment when choosing among therapies, as treatments do not necessarily lead 
to the same outcomes. If a child needs a rapid response within the first month, eltrombopag 
may be appropriate. If a child is being primarily treated due to the impact of ITP on their 
daily life, rituximab or eltrombopag may provide the greatest benefit, whereas if a child is 
being treated due to recurrent bleeding, romiplostim or rituximab may be most efficacious. 
With an improved understanding of the effect of each treatment on different outcomes in 
ITP, clinicians and families can select the optimal second-line treatment for an individual 
child using a shared-decision making approach.
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Figure 1. Outcomes by Treatment Group
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Table 2.











1 month 42 65 (4-230) 8 (19%) 15 (36%) 19 (45%)
6 months 33 151 (3-412) 17 (52%) 9 (27%) 7 (21%)
12 months 31 156 (4-408) 17 (55%) 8 (26%) 6 (19%)
Oral Immunosuppressants
1 month 16 60 (1-327) 2 (13%) 3 (19%) 11 (69%)
6 months 8 75 (11-261) 2 (25%) 1 (13%) 5 (63%)
12 months 4 75 (10-216) 1 (25%) 1 (25%) 2 (50%)
Romiplostim
1 month 29 67 (1-357) 6 (21%) 9 (31%) 14 (48%)
6 months 24 160 (6-598) 17 (71%) 3 (15%) 4 (17%)
12 months 16 147 (29-408) 9 (56%) 4 (25%) 3 (19%)
Eltrombopag
1 month 20 89 (10-402) 6 (30%) 5 (25%) 9 (45%)
6 months 15 97 (6-301) 4 (27%) 6 (40%) 5 (33%)
12 months 12 106(15-300) 5 (42%) 4 (33%) 3 (25%)
Complete platelet response defined as ≥50% of platelet counts >100 × 109/L since the prior study visit. A partial platelet response defined as ≥50% 
of platelet counts >30 × 109/L and twice the baseline platelet count. No response was defined as any platelet count change that did not meet criteria 
for CR or PR.
*
The platelet response did not significantly vary between treatments at 1 month (p=0.44). At 6 months, the platelet response varied significantly 
vary between treatments (p=0.04) with romiplostim showing the highest rate of complete response.
**
Patient attrition was seen at all time-points post-baseline. Due to patient attrition, the 12 month time-point was not considered in the primary 
analysis. Patients dropped out of their treatment group for various reasons (see Results).
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Table 3.
Skin and Non-Skin Bleeding Response by Treatment Group at 1, 6, and 12 months after starting treatment



































Baseline 43 81.4% 0.0004 <0.0001 53.5% 0.0006 0.003
1 month 42 42.9% 16.7%
6 months 33 36.4% 15.2%
12 months 29 34.5% 24.1%
Oral Immunosuppressants
Baseline 19 84.2% 0.04 0.21 52.6% 0.23 0.99
1 month 16 56.3% 31.3%
6 months 8 62.5% 50.0%
12 months 4 75% 50.0%
Romiplostim
Baseline 31 83.9% 0.011 0.024 58.1% 0.0001 0.264
1 month 29 48.3% 13.8%
6 months 24 50% 33.3%
12 months 16 18.8% 6.3%
Eltrombopag
Baseline 20 85% 0.33 0.005 50.0% 0.067 0.276
1 month 20 65% 20.0%
6 months 15 26.7% 20.0%
12 months 12 33.3% 16.7%
Grades 1 and 2 skin-related bleeding symptoms improved over time in all treatment groups (p<0.001).
Severe (Grade 2) non-skin bleeding (n) by treatment: Rituximab: baseline (n=10), 1 month (n=2), 6 months (n=1); oral immunosuppressants: 
baseline (n=7), 1 month (n=5), 6 months (n=2); Romiplostim: baseline (n=9), 1 month (n=2), 6 months (n=2); Eltrombopag: baseline (n=3), 1 
month (n=2); 6 months (n=1)
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Table 4.
Health Related Quality of Life as reported by child self or proxy-reported KIT scores by Treatment Group at 










Baseline 43 66.7 32.7-96.2 0.0001 <0.0001
1 month 42 75.2 35.6-97.1
12 months 31 85.2 47.1-100
Oral Immunosuppressants
Baseline 19 79.1 39.4-99.0 0.0006 <0.0001
1 month 16 87.1 53.8-97.1
12 months 4 94.5 86.5-100
Romiplostim
Baseline 31 75.6 51.0-98.1 0.0003 0.0001
1 month 29 83.7 57.0-98.1
12 months 16 87.5 70.2-99.0
Eltrombopag
Baseline 20 69.9 43.3-94.2 0.0008 0.0003
1 month 20 80.8 32.7-97.1
12 months 12 85.0 61.5-97.1
KIT: Kids ITP Tool
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